Drugs / Lisavanbulin
Lisavanbulin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03250299 | Dec 2017 → Jun 2022 | glioblastoma | Basilea Pharmaceutica | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02895360 | Aug 2016 → Aug 2020 | neoplasm | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1/2 | NCT02490800 | May 2015 → Sep 2022 | neoplasm | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1/2 | NCT01397929 | Jun 2011 → Jan 2016 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 20
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Basilea Pharmaceutica | Results Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA. |
| 2021-07-29 | Basilea Pharmaceutica | Regulatory Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea’s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). |
| 2021-06-07 | Basilea Pharmaceutica | Results Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting basilea.com ↗
The prevalence assessment of EB1-positivity or strong EB1-staining using immunohistochemistry methods presented at ASCO was based on 565 patient tissue samples from 14 different tumor types, including more than 100 glioblastoma samples. |
| 2020-09-22 | Basilea Pharmaceutica | Results Basilea reports data from poster presentations at ESMO Virtual Congress 2020 basilea.com ↗ |
| 2020-01-08 | Basilea Pharmaceutica | Results Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019 basilea.com ↗
Across the two studies, profound objective responses, with more than 80% reduction of the tumor area, were observed in two patients with glioblastoma, who continue to remain on treatment with lisavanbulin. |
| 2019-12-16 | Basilea Pharmaceutica | Results Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study basilea.com ↗
Across the two studies, profound objective responses, with more than 80% reduction of the GBM tumor area, were observed in two patients with glioblastoma, who continue to remain on treatment with lisavanbulin. |
| 2019-10-30 | Basilea Pharmaceutica | Results Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today presentations of supporting preclinical data, on its clinical stage oncology drug candidates derazantinib and lisavanbulin (BAL101553), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA, on October 29, 2019. |
| 2019-06-03 | Basilea Pharmaceutica | Results Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the phase 1 data from an ongoing study with the oral formulation of its novel tumor checkpoint controller, BAL101553, in brain cancer patients with progressive or recurrent glioblastoma, or high-grade glioma. |
| 2018-11-14 | Basilea Pharmaceutica | Results Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium basilea.com ↗
The first poster shows a highly synergistic anticancer effect of the combination of BAL101553 with eribulin in in-vitro cancer models. |
| 2018-06-05 | Basilea Pharmaceutica | Results Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting basilea.com ↗
The drug candidate showed initial signals of clinical activity as monotherapy and an acceptable safety profile supporting its advancement into phase 2a clinical development in targeted patient populations. |
| 2017-06-06 | Basilea Pharmaceutica | Results Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting basilea.com ↗
The overview and design of these ongoing studies as well as first interim data were presented at the ASCO meeting. |
| 2017-04-06 | Basilea Pharmaceutica | Results Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab basilea.com ↗
The preclinical data presented at the AACR meeting demonstrated that sub-cytotoxic concentrations of the active drug also directly interfered with the adaptation of tumor cells to oxygen deprivation. |
| 2016-06-09 | Basilea Pharmaceutica | Results Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting basilea.com ↗
The study showed signals of clinical activity at doses associated with a promising safety profile. |
| 2016-04-21 | Basilea Pharmaceutica | Results Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting basilea.com ↗
At the AACR meeting, preclinical data were presented demonstrating anti-cancer activity of BAL101553 against glioblastoma multiforme (GBM), a highly malignant form of brain cancer that has very limited treatment options and often has poor prognosis. |
| 2015-12-28 | Basilea Pharmaceutica | Results Basilea provides clinical program updates basilea.com ↗
Interim data from phase 1/2a study with tumor checkpoint controller BAL101553 show signals of clinical benefit |
| 2015-11-05 | Basilea Pharmaceutica | Results Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553 basilea.com ↗
The data demonstrate that BAL27862 (the active moiety of the prodrug BAL101553) has anti-proliferative activity against glioblastoma stem-like cells. |
| 2014-11-19 | Basilea Pharmaceutica | Results Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models basilea.com ↗
Intravenously or orally administered BAL101553 reduced tumor growth in a taxane-refractory animal model of human cancer, with daily or weekly oral administration eliciting equivalent anti-tumor responses. |
| 2014-06-02 | Basilea Pharmaceutica | Results Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study basilea.com ↗
The maximum tolerated dose (MTD) was determined and the results indicated first evidence of clinical antitumor activity. |
| 2014-04-07 | Basilea Pharmaceutica | Results Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR basilea.com ↗
BAL101553 demonstrated potent antitumor activity in diverse drug-refractory breast cancer models alone and in combination. |
| 2013-06-04 | Basilea Pharmaceutica | Results Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference basilea.com ↗
The presented data demonstrated that intravenously administered BAL101553 was well tolerated at the doses studied thus far and provided first evidence of anti-tumor activity. |
All press releases naming this drug 30 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lisavanbulin | “Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent.” PMID 36792805 ↗ Feb 2023 |
| Known as | BAL101553 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03250299 ↗ |
| Known as | Lisavanbulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297595 ↗ |
| Known as | Lisavanbuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297595 ↗ |
| Known as | MICROTUBULE-TARGETED AGENT BAL101553 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297595 ↗ |
| Modality | Small molecule | — CHEMBL4297595 ↗ |
| Route | Intravenous | “Intravenous administration” NCT01397929 ↗ |